切换至 "中华医学电子期刊资源库"
高级检索
中华肥胖与代谢病电子杂志

中华肥胖与代谢病电子杂志 ›› 2020, Vol. 06 ›› Issue (03) : 185 -190. doi: 10.3877/cma.j.issn.2095-9605.2020.03.009

所属专题： 文献；

论著

利拉鲁肽联合胰岛素泵对2型糖尿病伴代谢综合征患者代谢指标的影响
吴跃冠1,†(), 赵凡1, 邓素荣1   
  1. 1. 529000　江门，江门市人民医院内分泌科
  • 收稿日期:2020-05-26 出版日期:2020-08-30
  • 通信作者: 吴跃冠
  • 基金资助:
    2019年度江门市医疗卫生科技计划项目(江科【2019】101)

Impact of Lylalutide combined with insulin pump on metabolic indicators in patients with type 2 diabetes mellitus and metabolic syndrome

Yueguan Wu1,†(), Fan Zhao1, Surong Deng1   

  1. 1. Department of Endocrinology, Jiangmen People's Hospital, Jiangmen 529000, China
  • Received:2020-05-26 Published:2020-08-30
  • Corresponding author: Yueguan Wu
  • About author:
    Corresponding author: Wu Yueguan, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

吴跃冠, 赵凡, 邓素荣. 利拉鲁肽联合胰岛素泵对2型糖尿病伴代谢综合征患者代谢指标的影响[J]. 中华肥胖与代谢病电子杂志, 2020, 06(03): 185-190.

Yueguan Wu, Fan Zhao, Surong Deng. Impact of Lylalutide combined with insulin pump on metabolic indicators in patients with type 2 diabetes mellitus and metabolic syndrome[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2020, 06(03): 185-190.

目的

探讨利拉鲁肽联合胰岛素泵对2型糖尿病（T2DM）伴代谢综合征（MetS）患者的临床疗效及代谢指标的影响。

方法

选择2019年1月至2020年2月于江门市人民医院接受治疗的2型糖尿病伴MetS患者共60例，随机分为联合组和对照，其中联合组采用利拉鲁肽联合胰岛素泵治疗，对照组采用胰岛素泵治疗，比较两组患者的入院时及治疗2周、12周后的体质指标，以及血糖、糖化血红蛋白（HbA1c）及总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇（HDL-C）水平。

结果

两组患者治疗前的平均BMI、腰围、血压水平对比差异无统计学意义（P>0.05），治疗12周联合组的BMI和腰围水平显著低于治疗前，且低于对照组（P<0.05），两组患者治疗前的空腹和餐后2h的血糖水平，C肽水平和HbA1c对比差异无统计学意义（P>0.05），联合组的C肽水平在治疗2周、12周时显著高于对照组（P<0.05），且联合组的HbA1c水平在治疗2周、12周时显著低于对照组（P<0.05），两组患者治疗前的平均TC、TG、LDL-C、HDL-C水平对比差异无统计学意义（P>0.05），联合组在干预2周时的TC、LDL-C水平及干预12周时的TC、TG、LDL-C水平均显著低于对照组，而HDL-C水平显著高于对照组，差异具有统计学意义（P<0.05）。

结论

利拉鲁肽联合胰岛素泵可以有效改善T2DM合并MetS患者的体重，提高血糖控制效果，并改善血脂水平。

关键词: 利拉鲁肽, 胰岛素泵, 2型糖尿病, 代谢综合征, 血脂
Objective

To explore the effect of liraglutide combined with insulin pump on the clinical efficacy and metabolic indexes of patients with type 2 diabetes and metabolic syndrome.

Methods

A total of 60 patients with type 2 diabetes and MetS treated in our hospital from January 2019 to February 2020 were selected and randomly divided into a combined group and a control group. The combined group was treated with liraglutide combined with insulin pump. The control group was treated with an insulin pump, and the BMI, waist circumference, blood pressure, blood glucose, glycated hemoglobin (HbA1c), and blood lipids (Total cholesterol (TC), triglycerides (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) were compared between the two groups at the time of admission and after 2 and 12 weeks of treatment.

Results

There was no statistically significant difference in the average BMI, waist circumference and blood pressure before treatment between the two groups of patients (P>0.05). The BMI and waist circumference of the combined group after 12 weeks of treatment were significantly lower than before treatment and lower than the control group (P<0.05), the blood glucose level before treatment in both groups of patients, including fasting and 2h postprandial blood glucose levels, C peptide level and HbA1c difference was not statistically significant (P>0.05), the combination group C peptide level in treatment 2 Weeks and 12 weeks were significantly higher than the control group (P<0.05), and the HbA1c level of the combined group was significantly lower than the control group at 2 and 12 weeks of treatment (P<0.05). There was no significant difference in the average TC, TG, LDL-C, HDL-C levels between the two groups of patients before treatment (P>0.05). The levels of TC, TG and LDL-C were significantly lower than those of the control group, while the levels of HDL-C were significantly higher than that of the control group (P<0.05) .

Conclusions

In the perioperative period of weight loss and metabolic surgery, the implementation of rapid rehabilitation measures is superior to the traditional mode, which can significantly shorten the time of hospitalization, reduce postoperative complications, rapid recovery and save cost, and has outstanding application value.

Key words: Liraglutide, Insulin pump, Type 2 diabetes, Metabolic syndrome, Blood lipids
表1 两组患者一般资料比较
组别 N（例） 年龄（岁） 性别（男/女） 高血压（%） 冠心病（%） 吸烟（%） 病程（年）
联合组 30 52.4±4.3 18/12 22(47.9) 4(47.9) 6(14.7) 5.6±1.4
对照组 30 51.9±4.8 20/10 23(40.2) 5(40.2) 5(12.7) 5.7±1.9
t/χ2值 ? 0.425 0.287 0.089 0.131 0.111 0.232
P值 ? 0.672 0.592 0.766 0.718 0.739 0.817
表2 两组患者不同时间的体质指标对比
组别 N（例） BMI（kg/m2） 腰围（cm） 血压(mmHg)
收缩压 舒张压
联合组 30 ? ? ? ?
? 治疗前 ? 29.4±2.7 104.5±4.8 157±14 94±12
? 治疗后2周 ? 28.6±2.9 101.6±4.5* 155±14 92±13
? 治疗后12周 ? 27.4±2.1*# 97.3±3.9*# 151±13 91±12
对照组 30 ? ? ? ?
? 治疗前 ? 29.2±2.8 105.1±4.8 159±17 96±16
? 治疗后2周 ? 29.1±2.6 105.0±4.7 156±15 95±14
? 治疗后12周 ? 28.8±2.5 104.8±4.5 155±14 94±15
表3 两组患者不同时间的血糖相关指标对比
组别 N（例） 血糖（mmol/L） C肽（ng/ml） HbA1c（%）
空腹 餐后2 h
联合组 30 ? ? ? ?
? 治疗前 ? 8.6±1.8 14.7±3.2 1.7±0.5 8.7±0.9
? 治疗后2周 ? 7.3±1.4* 9.5±2.8* 2.4±0.4*# 7.8±0.5*#
? 治疗后12周 ? 6.9±1.3* 8.4±1.9* 2.9±0.5*# 6.6±0.4*#
对照组 30 ? ? ? ?
? 治疗前 ? 8.8±1.6 14.9±3.0 1.6±0.4 8.8±0.8
? 治疗后2周 ? 7.5±1.5* 9.8±2.4* 1.7±0.5 8.2±0.6*
? 治疗后12周 ? 7.1±1.4* 8.5±1.6* 1.8±0.5 7.4±0.5*
表4 两组患者不同时间的血脂相关指标对比
组别 N（例） TC（mmol/L） TG（mmol/L） LDL-C（mmol/L） HDL-C（mmol/L）
联合组 30 ? ? ? ?
? 治疗前 ? 5.14±0.73 3.23±0.41 3.35±0.45 0.86±0.15
? 治疗后2周 ? 4.72±0.54*# 3.02±0.37* 3.14±0.34*# 1.03±0.12*#
? 治疗后12周 ? 4.26±0.73*# 2.52±0.33*# 2.76±0.29*# 1.24±0.17*#
对照组 30 ? ? ? ?
? 治疗前 ? 5.18±0.71 3.25±0.44 3.39±0.41 0.87±0.14
? 治疗后2周 ? 5.05±0.65 3.19±0.42 3.35±0.42 0.90±0.11
? 治疗后12周 ? 4.85±0.67* 2.87±0.34* 3.14±0.27* 0.91±0.13
[1]
刘彦，吴波，曹雯，等．2型糖尿病患者腹臀脂肪与性别等因素的相关性研究[J/CD]．中华肥胖与代谢病电子杂志，2018，4(3)：129-135．
[2]
魏丹，孟化．BMI<35 kg/m2的肥胖症患者行代谢手术治疗的研究进展[J/CD]．中华肥胖与代谢病电子杂志，2018，4(3)：156-159．
[3]
Montanya E, Sesti G. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus[J]. Clin Ther, 2009, 31: 2472-2488.

URL    
[4]
Astrup A, Rossner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study[J]. Lancet, 2009, 374(9701): 1606-1616.
[5]
Rizzo M, Nikolic D, Banach M, et al. The effects of liraglutide on glucose, inflammatory markers and lipoprotein metabolism: current knowledge and future perspective[J]. Clin Lipidol, 2013, 8(2): 173-181..

URL    
[6]
Burgmaier M, Heinrich C, Marx N. Cardiovascular effects of glp-1 and glp-1-based therapies: implications for the cardiovascular continuum in diabetes[J]. Diabet Med, 2013, 30(3): 289-299.

URL    
[7]
Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human glp-1 analog, liraglutide[J]. Int J Obes (Lond), 2012, 36(6): 843-854.
[8]
中华医学会糖尿病学分会．中国2型糖尿病防治指南(2017年版)[J]．中华糖尿病杂志，2018，10(1)：4-67．
[9]
Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; american heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity[J]. Circulation, 2009, 120(16): 1640-1645.
[10]
Kostapanos MS, Katsiki N, Elisaf MS, et al. Editorial: reducing cardiovascular risk: Is low-density lipoprotein-cholesterol (ldl-c) lowering enough? [J]. Curr Vasc Pharmacol, 2012, 10(2): 173-177.

URL    
[11]
Sun F, Wu S, Guo S, et al. Effect of glp-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis[J]. Endocrine, 2015, 48(3): 794-803.
[12]
Yang SH, Xu RX, Cui CJ, et al. Liraglutide downregulates hepatic LDLreceptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1adependent mechanism[J]. Cardiovasc Diabetol, 2018, 17(1): 48.
[13]
Yan J, Yao B, Kuang H, et al. Liraglutide, sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease[J]. Hepatology (Baltimore, MD), 2019, 69(6): 2414-2426.
[14]
Li CJ, Li J, Zhang QM, et al. Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in chinese subjects with poorly controlled type 2 diabetes and abdominal obesity[J]. Cardiovasc Diabetol, 2012, 11: 142.
[15]
Feher M, Vega-Hernandez G, Mocevic E, et al. Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom[J]. Diabetes Ther, 2017, 8(2): 417-431.
[16]
Sposito AC, Berwanger O, Carvalho LS, et al. GLP-1RAs in type 2 diabetes:mechanisms that underlie cardiovascular effects and overview of cardiovascularoutcome data[J]. Cardiovasc Diabetol, 2018, 17(1): 157.
[17]
Tanaka A, Node K. Evidence-based and tailored medication in type 2 diabetes: a pathway learned from clinical trials[J]. Cardiovasc Diabetol, 2019, 18(1): 19.
[18]
Chen XM, Zhang WQ, Tian Y, et al. Liraglutide suppresses non-esterified free fatty acids and soluble vascular cell adhesion molecule-1 compared with metformin in patients with recent-onset type 2 diabetes[J]. Cardiovascular diabetology, 2018, 17(1): 53.
[19]
Fan Q, Yin X, Rababa’h A, et al. Absence of Gravin Mediated Signaling Inhibits Development of High Fat Diet-Induced Hyperlipidemia and Atherosclerosis[J]. Am JPhysiol Heart Circ Physiol, 2019, 317: 793-810.
[1] 何金梅, 尹立雪, 谭静, 张文军, 王锐, 任梅, 廖明娇. 超声心肌做功技术对2型糖尿病患者潜在左心室心肌收缩功能损伤的评价[J]. 中华医学超声杂志（电子版）, 2023, 20(10): 1029-1035.
[2] 郑希彦, 周正, 何方平, 林志群, 杜飞, 谢琴, 王少平, 史宪杰. 代谢综合征与乙型肝炎病毒相关性肝细胞癌预后的危险因素分析[J]. 中华普通外科学文献(电子版), 2023, 17(02): 104-109.
[3] 胡守芳, 吴霞, 陈与知. 司美格鲁肽联合头孢哌酮钠舒巴坦治疗2型糖尿病并发肺炎的临床分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(01): 43-46.
[4] 邓荣珍, 罗宇珍, 赵若蓓, 邓杨, 廖蕴华, 潘玲. 血脂与IgA肾病患者肾脏预后的相关性研究[J]. 中华肾病研究电子杂志, 2023, 12(01): 13-19.
[5] 李茹月, 庞睿奇, 王宁利. 血脂异常与原发性开角型青光眼发病相关性的研究进展[J]. 中华眼科医学杂志(电子版), 2023, 13(01): 35-39.
[6] 李田利, 张照龙, 孙成建, 刘国平, 谢宜兴, 赵晓龙, 邵黎明, 郑璇, 王长鑫, 徐锐. 基于血流动力学、血脂及外周血炎症标志物的眼段动脉瘤破裂风险相关研究[J]. 中华消化病与影像杂志(电子版), 2023, 13(02): 78-83.
[7] 薛念余, 张盛敏, 吴凌恒, 沙蕾, 童揽月, 沈崔琴, 李朝军, 杜联芳. 研究血清胆红素对2型糖尿病患者心脏结构发生改变前心肌功能的影响[J]. 中华临床医师杂志(电子版), 2023, 17(9): 1004-1009.
[8] 陶璐, 初楠, 韩洁, 白春英, 逄雯丽, 余海源. 血清PECAM-1、Sirt1水平与2型糖尿病患者颈动脉粥样硬化的关系[J]. 中华临床医师杂志(电子版), 2023, 17(03): 291-296.
[9] 韩家超, 王飞飞, 柳子宁, 胡冀陶, 孟泽松, 雒月云, 王贵英. 二甲双胍的作用机制研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(03): 349-355.
[10] 汪赓, 夏泽锋, 陶凯雄. 代谢手术在非肥胖型2型糖尿病中的治疗效果及研究进展[J]. 中华肥胖与代谢病电子杂志, 2023, 09(03): 155-160.
[11] 李锦亮, 曾茂娟, 钟金宝, 何伟强, 林文新. 司美格鲁肽对肥胖2型糖尿病患者皮肤微循环功能的影响[J]. 中华肥胖与代谢病电子杂志, 2023, 09(03): 192-196.
[12] 戚晓阳, 杨平, 杜忠秋, 邱旭升, 汤黎明, 陈一心. 袖状胃切除术对肥胖合并2型糖尿病大鼠模型骨密度的影响[J]. 中华肥胖与代谢病电子杂志, 2023, 09(02): 102-108.
[13] 晋连超, 杨冰, 周哲, 潘东亮, 谢遵珂. 代谢综合征与女性压力性尿失禁相关性研究[J]. 中华肥胖与代谢病电子杂志, 2023, 09(02): 109-113.
[14] 穆曼娜, 胡莹清, 李远, 张勇军, 胡细玲, 林倍思, 刘德昭. 氯雷他定联用普瑞巴林治疗2型糖尿病皮肤瘙痒症的临床效果评价[J]. 中华肥胖与代谢病电子杂志, 2023, 09(02): 114-119.
[15] 秦晓光, 毛忠琦, 周晓庆, 谢尔凡, 吴国强, 张敏, 李威杰. 单吻合口胃旁路术对于肥胖及糖尿病患者心脑血管风险的影响[J]. 中华肥胖与代谢病电子杂志, 2023, 09(02): 120-125.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号